This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): Revestive (EU), ALX-0600, teduglutide, recombinant GLP-2, SHP633, SHP 633, SHP-633
Description: Gattex (teduglutide) is an analog of glucagon-like peptide-2 (GLP-2), a naturally occurring hormone that regulates the growth, proliferation and maintenance of the cells lining the small intestine. Animal studies have indicated that administration of teduglutide produces a significant increase in both the mass and absorptive surface area of this lining. Gattex also has a pronounced effect on reducing gut permeability in animal models. In addition, based on studies done to date, Gattex appears to have biological activity exclusively in the gastrointestinal system. Gattex differs from GLP-2 by only one amino acid. This change increases the plasma half-life of the drug.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
NPS Pharmaceuticals and Nycomed
In September 2007, NPS Pharmaceuticals and Nycomed entered into a definitive agreement which licenses to Nycomed the rights to develop and commercialize Gattex outside the United States, Canada and Mexico for the treatment of gastrointestinal disorders. NPS will retain the right to develop and commercialize Gattex in North America.
Under the terms of the agreement, NPS has the potential to earn up to $185 million plus royalties. As an upfront payment, NPS will receive from Nycomed $35 million: a $10 million nonrefundable commitment fee upon signing the agreement and $25 million within two weeks following the announcement of topline results from the recently completed Phase III study of Gattex in patients with short bowel syndrome (SBS). Nycomed has the right to end the collaboration within two weeks of the announcement of these results and forego the $25 million payment.
Additional information available to subscribers only: